Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 14/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 13/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 13/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19226663 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1TSHR | |
| SCHEMBL19485353 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1TSHR | |
| SCHEMBL18649667 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1TSHR | |
| SCHEMBL18431542 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1TSHR | |
| SCHEMBL21524575 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1TSHR | |
| SCHEMBL19302473 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1TSHR | |
| SCHEMBL4893032 | 0.98 | GNAO1 (0.43) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL21166114 | 0.96 | GNAO1 (0.43) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL21499910 | 0.93 | GNAO1 (0.41) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL21214226 | 0.92 | GNAO1 (0.43) | GNAO1GNAI3GNAI1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10398721-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-9682097-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | AURKA, AURKC, AURKB | GNAO1 1592/4885GNAI3 1065/4885GNAI1 847/4885 |
| US-10398721-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | LMNA, LMNB2, LMNB1 | GNAO1 519/4885GNAI3 1448/4885GNAI1 1599/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | GNAO1 1358/4885GNAI3 798/4885GNAI1 627/4885 |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | GNAO1 3033/4885GNAI3 2137/4885GNAI1 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.